Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | FLT3 | P36888 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321603 | 0.84 | FLT3 (0.62) | KDRFLT3FGFR3 | |
| SCHEMBL5252965 | 0.83 | KDR (0.68) | KDRFLT3 | |
| SCHEMBL5249616 | 0.81 | KDR (0.45) | KDRFLT3FGFR3 | |
| SCHEMBL3177430 | 0.78 | FLT3 (0.46) | KDRFLT3 | |
| SCHEMBL3185876 | 0.78 | FLT3 (0.43) | KDRFLT3FGFR3 | |
| SCHEMBL17556152 | 0.77 | KDR (0.82) | KDRFLT3 | |
| SCHEMBL13363815 | 0.77 | KDR (0.41) | KDRFLT3 | |
| SCHEMBL16965212 | 0.77 | FLT3 (0.48) | KDRFLT3 | |
| SCHEMBL16965613 | 0.76 | KDR (0.74) | KDRFLT3FGFR3 | |
| SCHEMBL3323502 | 0.76 | FLT3 (0.39) | KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745400-B2 | Inhibition of BMP signaling, compounds, compositions and uses thereof | VANDERBUILT UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284183-A1 | INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284183-A1 | INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF | BMP1, BMP4, BMP2 | KDR 362/4885FLT3 190/4885MEN1 525/4885 |
| US-10745400-B2 | Inhibition of BMP signaling, compounds, compositions and uses thereof | BMP1, BMP4, BMP2 | KDR 362/4885FLT3 190/4885MEN1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.